Founded by Flagship Pioneering in 2020, Empress Therapeutics generates good medicines, fast, by starting with chemistry inside the human body. The Empress Chemilogics(TM) platform uses novel insights that connect the lines of code in DNA with drug-like chemistry made in the human body to create first- or best-in-class oral medicines for a broad range of diseases quickly, predictably, and cost-effectively.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $50M
Founded date: 2022
Investors 1
| Date | Name | Website |
| 07.11.2023 | J2 Venture... | j2vp.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.06.2023 | - | $50M | - |
Mentions in press and media 1
| Date | Title | Description |
| - | Empress Therapeutics | “We access the vast untapped universe of chemistry encoded in DNA found inside the human body to rapidly generate safe, effective, oral medicines with the potential to treat nearly every major disease area.” |